The largest database of trusted experimental protocols

4 protocols using recombinant human sdf 1α cxcl12

1

Electrospun PCL Scaffolds with LbL Coatings

Check if the same lab product or an alternative is used in the 5 most similar protocols
The reagents for electrospinning, PCL (Mw =80 kDa), dichloromethane and dimethyl sulfoxide (DMSO), were purchased from Sigma-Aldrich (USA). The reagents for LbL self-assembly, polyallylamine hydrochloride (PAH), CS (Mw=50-190 kDa) and HA (Mw=1500-1800 kDa) were also obtained from Sigma-Aldrich (USA). Dulbecco’s modified Eagle’s medium (DMEM), PBS, Fetal bovine serum (FBS), penicillin–streptomycin and trypsin were purchased from Gibco (USA). Recombinant human BMP-2 (rhBMP-2) and recombinant human SDF-1α/CXCL12 were purchased from Peprotech (USA).
+ Open protocol
+ Expand
2

Investigating PDGF-BB and SDF-1α Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human PDGF-BB protein was purchased from Novus Biologicals (cat. no. NBP2-35203), LLC. Recombinant human SDF-1α (CXCL12) was obtained from PeproTech (cat. no. 300-28A), Inc. AMD3100 (a CXCR4 inhibitor, cat. no. S8030) and niclosamide (a STAT3 inhibitor, cat. no. S3030) were purchased from Selleck Chemicals. Anti-CXCR4 (cat. no. ab124824, 1:100), anti-CXCR7 (cat. no. ab72100, at 6 µg/ml), and anti-PDGFR-β (cat. no. ab69506, at 1 µg/ml) were obtained from Abcam. Anti-β-tubulin was obtained from Absin Biotechnology Co., Ltd (cat. no. abs830032, at 0.5 µg/ml). Anti-STAT3 (cat. no. ET1605-45, 1:1,000) and anti-phosphorylated (p)-STAT3 (cat. no. ET1603-40, 1:1,000) were obtained from Hangzhou Hua'An Biotechnology Co., Ltd. Anti-ERK-1/2 (cat. no. 9102, 1:1,000), anti-p-ERK1/2 (cat. no. 9106, 1:2,000), anti-AKT (cat. no. 9272, 1:1,000), and anti-p-AKT (cat. no. 9611, 1:1,000) were obtained from Cell Signaling Technology, Inc. Anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibodies (cat. no. A0216, 1:1,000) and anti-rabbit HRP-conjugated secondary antibodies (cat. no. A0208, 1:1,000) were obtained from Beyotime Institute of Biotechnology. Primary Antibody Dilution Buffer (cat. no. P0023A) and Secondary Antibody Dilution Buffer (cat. no. P0023D) were also obtained from Beyotime Institute of Biotechnology.
+ Open protocol
+ Expand
3

Preparation of Inhibitor Solutions

Check if the same lab product or an alternative is used in the 5 most similar protocols
A selective HCK inhibitor, iHCK-37 (ASN05260065; ASINEX company), was diluted in dimethylsulfoxide (Me2SO4; DMSO) to a 100 mM stock solution. AMD3100 (Sigma-Aldrich) was diluted in water to a 100 mM stock solution. Recombinant Human SDF-1α (CXCL12, PeproTech) was diluted in PBS buffer to a 100 ng/μL stock solution.
+ Open protocol
+ Expand
4

Intra-renal Injection of CXCL12 in Cats

Check if the same lab product or an alternative is used in the 5 most similar protocols
Before injections, Treatment group cats were fasted and pre-medicated with diazepam IV. IV catheters were placed, and LRS was administered IV. Propofol was used for anesthesia induction, and anesthetic plane was maintained using isoflurane in oxygen via mask or endotracheal tube. Bilateral flanks were shaved, and renal ultrasound was performed in lateral recumbency for each kidney. Each flank was prepared for aseptic ultrasound-guided intra-renal injection. Using a sterile-covered convex probe to obtain a longitudinal view of the kidney, a single injection was administered into the middle of each kidney mid-cortex level using a sterile 27-gauge needle to deliver 0.25 ml of sterile saline plus 200 ng CXCL12 (Recombinant Human SDF-1α (CXCL12), Catalog #300-28A, PeproTech Inc., Rocky Hill, NJ) that was reconstituted and aliquoted sterilely using a 0.45 um filter. All treatment injections were performed by the same two investigators who were trained in the technique used in the I/R study.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!